Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803683 | 0.86 | CTSK (0.39) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL499190 | 0.84 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL499191 | 0.84 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL3639189 | 0.81 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL3639191 | 0.81 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL24991144 | 0.81 | CTSK (0.37) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL1447140 | 0.79 | HDAC6 (0.36) | CTSKCTSSCTSLCTSBHTR2C | |
| SCHEMBL3770470 | 0.79 | CTSK (0.37) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL3770473 | 0.79 | CTSK (0.37) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL8911411 | 0.79 | HTR2C (0.42) | CTSKCTSSCTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2008156832-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | ACE, REN, ACE2 | CTSK 101/4885CTSS 64/4885CTSL 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.